BioPharmX
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, BioPharmX sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
BioPharmX: 6 sponsored US clinical trials, none currently recruiting.
BioPharmX sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 1 trials.
Upper-quartile sponsor footprint
BioPharmX sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea
NCT03050086
Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
NCT02946788
BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris
NCT02815332
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
NCT02709096
Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline
NCT02695446
A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness
NCT02676336
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 4 | 1 |
Therapeutic Areas
How the BioPharmX early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 6 completed (100%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Acne Vulgaris (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
BioPharmX: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
BioPharmX sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this BioPharmX page
6 registered trials is a research-attention snapshot, not an endorsement of BioPharmX or any single study.
- None of BioPharmX's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Acne Vulgaris is the condition BioPharmX studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioPharmX pipeline card: 6 registered trials from official public datasets.Report a data error.